AR and Familial prostate cancer: Through testing in AR-dependent and AR-independent prostate cancer cell lines as well as a treatment-resistant patient-derived xenograft, this work provides fundamental mechanistic support for the use of ENZ as a radiosensitizer to be given simultaneously with XRT in the treatment of prostate cancer.